Tyce J. Kearl, MD, PhD

Assistant Professor

Contact Information

Education

Fellowship in Pediatric Oncology/Hematology, MCW, 2017-2020
Pediatric Residency, University of Wisconsin, 2014-2017
MD, MCW, 2014
PhD in Microbiology and Molecular Genetics, MCW, 2012
BA, Utah State University, 2006

Biography

Tyce Kearl, MD, PhD, is an assistant professor of medicine (hematology and oncology) at the 91大神 College of Wisconsin. His specialization is in pediatric cancers and he practices at Children’s Wisconsin. He obtained his undergraduate degree at Utah State University and then entered the 91大神 Scientist Training Program at the 91大神 College of Wisconsin where he obtained his doctoral degree in 2012 and his medical degree in 2014. He completed his residency in Pediatrics at the University of Wisconsin in 2017 and the completed his fellowship in pediatric hematology and oncology at the 91大神 College of Wisconsin.

Research Interests

As a physician scientist specializing in pediatric oncology, I am focused on improving the treatment of childhood and adult cancers through immune-based therapies. My recent research has involved generating novel chimeric antigen receptor (CAR) T-cells and using advanced genetic techniques such as single-cell RNA sequencing to identify mechanisms of resistance to CAR T-cell therapy.

(Quamine A, Mohrdieck NR, King CA, Griggs AA, Kline JM, Cho MM, Rinella SP, Tippins KE, Bates PD, Shi L, Song L, Hess NJ, Kearl TJ, Johnson BD, Capitini CM.) bioRxiv. 2024 Jul 12 PMID: 39026718 PMCID: PMC11257576 07/19/2024
(Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV, Bruening J, Massey B, Wong S, Shreenivas A, Shukla M, Kasprzak J, Sun Y, Shaheduzzaman M, Chen F, Kearl T, Himburg HA.) Transl Oncol. 2024 Apr;42:101899 PMID: 38320395 PMCID: PMC10851216 SCOPUS ID: 2-s2.0-85184507548 02/07/2024
(Zenga J, Himburg HA, Wong SJ, Kearl T, Hematti P, Jin VX, Memon AA, Mathison AJ, Awan MJ.) Oral Oncology. September 2024;156 SCOPUS ID: 2-s2.0-85198374252 09/01/2024
(Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV, Bruening J, Massey B, Wong S, Shreenivas A, Shukla M, Kasprzak J, Sun Y, Shaheduzzaman M, Chen F, Kearl T, Himburg HA.) Translational Oncology. June 2024;44 SCOPUS ID: 2-s2.0-85187349354 06/01/2024
(Thakar MS, Kearl TJ, Malarkannan S.) Front Oncol. 2019;9:1529 PMID: 32076597 PMCID: PMC7006459 02/23/2020
(Kearl TJ, Jing W, Gershan JA, Johnson BD.) J Immunol. 2013 Jun 01;190(11):5620-8 PMID: 23616570 PMCID: PMC3891840 SCOPUS ID: 2-s2.0-84878099006 04/26/2013
(Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M.) Biochim Biophys Acta. 2012 Dec;1821(12):1501-7 PMID: 22960380 PMCID: PMC3809829 SCOPUS ID: 2-s2.0-84866500244 09/11/2012
(Dice MS, Kearl T, Ruben PC.) Methods Mol Med. 2006;129:163-85 PMID: 17085811 SCOPUS ID: 2-s2.0-35548949165 11/07/2006

91大神